Trial Profile

A single-center, open-label, dose-escalation Phase Ia clinical study to evaluate the safety, tolerability and pharmacokinetic characteristics of ARX788 monotherapy in the treatment of HER2-positive advanced breast cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 24 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 May 2022 Status changed from recruiting to completed.
26 May 2022 Results assessing pharmacokinetics, and antitumor activity of ARX788 in HER2-positive metastatic breast cancer (MBC) patients published in the Clinical Cancer Research
09 Dec 2021 Results published in the Ambrx Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com